title: Chronic hepatitis C therapy: a rare complication revisited.
abstract: The combined regimen of peg-interferon α2a plus ribavirin along with protease inhibitors (boceprevir or telaprevir) is considered as a very portent and effective therapy for hepatitis C infections. However, this combined therapy has been associated with a side effect that can make the course of the disease more complicated. In this case, a 50-year-old man developed insulin-dependent diabetes soon after initiating triple hepatitis C therapy. The treatment had to be stopped and the course of his hepatitis C infection has been challenged with this rare side effect.
authors.affiliation: Department of Medicine, University Hospital, Case Western Reserve, Cleveland, Ohio, USA.
authors.forename: Mohammed Eyad Yaseen
authors.initials: ME
authors.lastname: Alsabbagh
authors.forename: Naseem
authors.initials: N
authors.lastname: Eisa
authors.forename: Abdul Hamid
authors.initials: AH
authors.lastname: Alraiyes
authors.forename: M Chadi
authors.initials: MC
authors.lastname: Alraies
mesh_terms: D000279:Administration, Cutaneous; D000998:Antiviral Agents / Q000009:adverse effects*; D003922:Diabetes Mellitus, Type 1 / Q000139:chemically induced*; D004359:Drug Therapy, Combination; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000009:adverse effects; D011994:Recombinant Proteins / Q000009:adverse effects; D012254:Ribavirin / Q000009:adverse effects
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D009842:Oligopeptides; D011994:Recombinant Proteins; D012254:Ribavirin; C486464:telaprevir
references.citation: N Engl J Med. 2011 Jun 23;364(25):2405-16
references.pmid: 21696307
references.citation: Endocr J. 2010;57(11):947-51
references.pmid: 20805634
references.citation: J Hepatol. 1996 Jan;24(1):38-47
references.pmid: 8834023
references.citation: J Gastrointestin Liver Dis. 2013 Mar;22(1):101-4
references.pmid: 23539399
references.citation: Biochem Biophys Res Commun. 1993 Nov 30;197(1):22-7
references.pmid: 7504484
references.citation: Hepatology. 2006 Apr;43(4):661-72
references.pmid: 16557537
references.citation: Lancet. 1992 Aug 29;340(8818):548
references.pmid: 1354296